Search

Your search keyword '"Perry, Jacqueline"' showing total 64 results

Search Constraints

Start Over You searched for: Author "Perry, Jacqueline" Remove constraint Author: "Perry, Jacqueline" Database Unpaywall Remove constraint Database: Unpaywall
64 results on '"Perry, Jacqueline"'

Search Results

2. Supplementary Figures and Tables from MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology

3. Supplementary Figures and Tables from MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology

4. Data from MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology

5. P-092 High serum free light chains levels in African ancestry population screened for monoclonal gammopathy: implication for definition of FLC reference range accounting for renal function and race

6. OA-35 High-throughput plasma proteomics to define the precursor multiple myeloma proteome and identify candidate high-risk disease biomarkers of progression

7. P-097 Single-cell RNA sequencing of circulating tumor cells in precursor myeloma patients reveals early mechanisms of disease dissemination

8. Abstract 796: Altered immune response to vaccination in patients with plasma cell premalignancy

9. Data from MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology

10. Supplementary Figures and Tables from MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology

11. Supplementary Figures and Tables from MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology

12. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study

13. MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology

14. Monitoring Plasma Cells and Clonal Emergence through Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma

15. Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation

16. High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients

17. Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology

18. Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM

20. Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability

21. Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa

22. Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study

23. Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race

24. P-055: Monitoring the emergence of multiple myeloma high-risk subclones with whole-genome sequencing of circulating tumor cells

25. OAB-036: The PANGEA model: dynamic modeling for personalized prediction of precursor disease progression to multiple myeloma

26. Abstract 3582: Single-cell RNA-sequencing for immune profiling of SARS-CoV2 vaccine response in healthy individuals and patients with precursor plasma cell malignancies

27. Abstract 3651: Obesity, metabolic comorbidities, and lifestyle factors and their association with monoclonal gammopathies in a high-risk screened population: Results of the PROMISE study

28. Abstract 641: Single-cell RNA sequencing of rare circulating tumor cells in precursor myeloma patients reveals molecular underpinnings of tumor cell circulation

29. Abstract 5277: Humoral SARS-CoV-2 response in asymptomatic precursor plasma cell dyscrasia patients: IMPACT study results

30. Abstract 2259: Predictive modeling of smoldering multiple myeloma progression to multiple myeloma by continuous variable analysis

31. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study

32. Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia

33. Mass Spectrometry-Detected Monoclonal Gammopathy of Undetermined Significance is Associated with Obesity and Other Novel Modifiable Risk Factors: Results of the Promise Study

34. High Prevalence of Monoclonal Gammopathy in a Population at Risk: The First Results of the Promise Study

35. Social Determinants of Health and COVID-19 Behaviors and Beliefs Toward Immunizations Among Latinxs

36. Prevalence of Monoclonal Gammopathies Including an Age-Related Monoclonal Gammopathy of Indeterminate Potential (MGIP) in a Racially Diverse US Population Screened by Mass Spectrometry

37. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: A prospective cohort study

39. Preformed Donor-specific Antibodies Against HLA Class II and Graft Outcomes in Deceased-donor Kidney Transplantation

49. Dimensional phenotypic analysis and functional categorisation of mutations reveal novel genotype–phenotype associations in Rett syndrome

Catalog

Books, media, physical & digital resources